Skip to main content
SpringerLink
Log in

Pulmonale Manifestationen rheumatologischer Erkrankungen

  • Chapter
  • First Online:
Seltene Lungenerkrankungen

  • 3306 Accesses

Zusammenfassung

Kollagenosen können diverse pulmonale und thorakale Manifestationen aufweisen. Hierbei sind kollagenoseassoziierte interstitielle Lungenerkrankungen (CTD-ILD) eine der wichtigsten Differenzialdiagnosen interstitieller Lungenerkrankung. Zumeist findet sich ein NSIP-Muster, allerdings können alle Muster bis hin zur alveolären Hämorrhagie auftreten. Zudem ist die Abgrenzung zu infektiösen Komplikationen oder zur medikamentenassoziierten ILDs zum Teil komplex. Eine Indikation zur immunsuppressiven Therapie bei CTDILDs ist für progrediente und/oder klinisch signifikante Erkrankungen reserviert und sollte in enger Absprache mit dem betreuenden Rheumatologen erfolgen. Eine weitere wichtige Organmanifestation ist die kollagenoseassoziierte pulmonale Hypertonie. Daneben kann es auch zu Bronchiektasen/Bronchiolitiden, zu pleuralen Affektionen oder auch zu einer Mitbeteiligung der Atemmuskulatur kommen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Altmann RD, Medsger TA Jr, Bloch DA, Michel BA (1991) Predictors of survival in systemic sclerosis. Arthritis Rheum 34:403–413

    Article  Google Scholar 

  • Avouac J, Huscher D, Furst DE et al (2014) Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. Ann Rheum Dis 73(1):191–197

    Article  PubMed  Google Scholar 

  • Bouros D, Wells AU, Nicholson AG et al (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165:1581–1586

    Article  PubMed  Google Scholar 

  • Burt RK, Shah SJ, Dill K et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis: an open-label, randomised phase 2 trial. Lancet 378:498–506

    Article  CAS  PubMed  Google Scholar 

  • Cervera R, Khamashta MA, Font J et al (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 78:167–175

    Article  CAS  Google Scholar 

  • Christian RB, Wells AU, Capelozzi VL, Silver RM (2010) Gastroesophagela reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheuma 40:21–249

    Google Scholar 

  • Coghlan JG, Denton CP, Grünig E et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73(7):1340–1349 (DETECT Study Group)

    Article  PubMed Central  PubMed  Google Scholar 

  • Cottin V (2013) Significance of connective tissue diseases features in pulmonary fibrosis. Eur Respir Rev 22:273–280

    Article  PubMed  Google Scholar 

  • Dekan G (2003) Histologische Klassifikation interstitieller Lungenerkrankungen. Z Rheumatol 62:16–20

    Article  PubMed  Google Scholar 

  • Fischer A, Brown KK, Du Bois RM et al (2013) Mycophenolatemofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40(5):640–646

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Highland KB, Garin MC, Brown KK (2007) The spectrum of scleroderma lung disease. Semin Respir Crit Care Med 28:418–429

    Article  PubMed  Google Scholar 

  • Hwang JH, Misumi S, Sahin H et al (2009) Computed tomographic features of idiopathic fibrosing interstitial pneumonia: comparison with pulmonary fibrosis related to collagen vascular disease. J Comput Assist Tomogr 33:410–415

    Article  PubMed  Google Scholar 

  • Hyldgaard C, Hilberg O, Muller A, Bendstrup E (2014) A cohort study of interstitial lung diseases in central Denmark. Respir Med 108(5):793–799

    Article  PubMed  Google Scholar 

  • Jagirdar J, Chikkamuniyappa S, Sirohi D (2013) Cystic lung lesions in Sjogrens syndrome: analysis of lymphocyte subsets in tissue with clinico-radiologic-pathologic correlation. Annals of Diagnostic Pathology 17:113–116

    Article  PubMed  Google Scholar 

  • Kalluri M, Oddis CV (2010) Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med 31:501–512

    Article  PubMed  Google Scholar 

  • Keir G, Maher TM, Ming D et al (2014) Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19:353–359

    Article  PubMed  Google Scholar 

  • Koreeda Y, Higashimoto I, Yamamoto M et al (2010) Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoanibodies. Intern Med 4:361–369

    Article  Google Scholar 

  • Kowal-Bielecka O, Landewe R, Avouac J et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR scleroderma trials and research group (EUSTAR). Ann Rheum Dis 68:620–628

    Article  CAS  PubMed  Google Scholar 

  • Kreider M, Highland K (2014) Pulmonary Involvement in Sjögren Syndrome. Semin Respir Crit Care Med 35:255–264

    Article  PubMed  Google Scholar 

  • van Laar JM, Farge D, Sont JK et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490–2498 (EBMT/EULAR Scleroderma Study Group)

    Article  PubMed  Google Scholar 

  • Nannini C, Jebakumar AJ, Crowson CS (2013) Primary Sjogren’s syndrome 1976–2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open 3(11):e003569

    Article  PubMed Central  PubMed  Google Scholar 

  • Nikpour M, Baron M (2014) Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol 26:131–137

    Article  PubMed  Google Scholar 

  • Park JH, Kim DS, Park IN et al (2007) Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 175:705–711

    Article  PubMed  Google Scholar 

  • Le Pavec J, Girgis RE, Lechtzin N et al (2011) Systemic sclerosisrelated pulmonary hypertension associated with interstitiallung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 63:2456–2464

    Article  PubMed  Google Scholar 

  • Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C et al (2011) Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 41:256–264

    Article  CAS  PubMed  Google Scholar 

  • Prasse A, Costabel U (2008) Lungenbeteiligung bei Systemerkrankungen. In: Matthys H, Seeger W (Hrsg) Klinische Pneumologie, 4. Aufl. Springer Verlag, Heidelberg

    Google Scholar 

  • Romagnoli M, Nannini C, Piciucchi S et al (2011) Idiopathic nonspecific interstitial pneumonia. An interstitial lung disease associated with autoimmune disorders? Eur Respir J 38:384–391

    Article  CAS  PubMed  Google Scholar 

  • Schotte H, Becker H, Domschke W, Gaubitz M (2005) Kardiovaskuläres Monitoring von Patienten mit systemischem Lupus erythematodes. Z Rheumatol 64(8):564–575

    Article  CAS  PubMed  Google Scholar 

  • Solomon JJ, Chartrand S, Fischer A (2014) Current approach to connective tissue disease-associated interstitial lung disease. Curr Opin Pulm Med 20:449–456

    Article  PubMed  Google Scholar 

  • Solomon JJ, Olson AL, Fischer A (2013) Scleroderma Lung Disease. Eur Respir Rev 22(127):6–19

    Article  PubMed Central  PubMed  Google Scholar 

  • Tahskin DP, Elashoff R, Clements PF et al (2006) Cyclophosphamide versus placebo scleroderma lung disease. N Engl J Med 354:2655–2666

    Article  Google Scholar 

  • Tahskin DP, Elashoff R, Clements PJ et al (2007) Effects of 1-year treatment with cyclophosphamide on outcoes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176:1026–1034

    Article  Google Scholar 

  • Tyndal AJ, Baner B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809–1815

    Article  Google Scholar 

  • Valeyre D, Duchemann B, Nunes H, Uzunhan Y, Annesi-Maesanoin I (2014) Interstitial lung diseases. In: Welte T (Hrsg) ERS monograph, Respiratory Epidemiology, S 79–87

    Google Scholar 

  • Vij E, Strek ME (2013) Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 143:814–824

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Walker WC, Wright V (1968) Pulmonary lesions and rheumatoid arthritis. Medicine 47:501–520

    Article  CAS  PubMed  Google Scholar 

  • Winstone TA, Assayag D, Wilcox PG et al (2014) Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 146:422–436

    Article  PubMed  Google Scholar 

  • Yang X, Mardekian J, Sanders KN, Mychaskiw MA, Thomas J 3rd (2013) Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol 32(10):1519–1531

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thoraxklinik, Pneumologie und Beatmungsmedizin, Universitätsklinikum Heidelberg, Röntgenstr. 1, 69126, Heidelberg, Deutschland

    Prof. Dr. med. Michael Kreuter

  2. Medizinische Klinik und Poliklinik V, Sektion Rheumatologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Deutschland

    Prof. Dr. med. Hanns-Martin Lorenz

  3. Abteilung für Pneumologie, Klinik Schillerhöhe, Solitudenstr. 18, 70839, Stuttgart-Gerlingen, Deutschland

    Prof. Dr. med. Martin Kohlhäufl

Authors
  1. Prof. Dr. med. Michael Kreuter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Hanns-Martin Lorenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. Martin Kohlhäufl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Kreuter .

Editor information

Editors and Affiliations

  1. Pneumologie und Beatmungsmediz, Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Michael Kreuter

  2. Ruhrlandklinik, Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany

    Ulrich Costabel

  3. Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Felix Herth

  4. Zentrum für Pneumologie & Thoraxchir., LungenClinic Großhansdorf, Großhansdorf, Schleswig-Holstein, Germany

    Detlef Kirsten

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kreuter, M., Lorenz, HM., Kohlhäufl, M. (2016). Pulmonale Manifestationen rheumatologischer Erkrankungen. In: Kreuter, M., Costabel, U., Herth, F., Kirsten, D. (eds) Seltene Lungenerkrankungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48419-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48419-7_8

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48418-0

  • Online ISBN: 978-3-662-48419-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation